Refractory Chronic Cough and Unexplained Chronic CoughPhase 2SensoryCloudNCT07690059
A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough
A Phase 2 study testing SC0032 in people with Refractory Chronic Cough and Unexplained Chronic Cough, run by Sensory Cloud, Inc. at 3 sites in United Kingdom.
Trial summary
This is a randomized placebo-controlled, parallel-arm study to determine the safety and efficacy of SC0032 in participants with RCC Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Refractory Chronic Cough and Unexplained Chronic Cough
- What is being tested?
- SC0032
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 3 sitesUnited Kingdom
- Study dates
- 13 Jul 2026to Apr 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Males and females between 18 and 80 years.
- Capable of giving signed informed consent.
- Diagnosed with RCC (including unexplained chronic cough) for at least 6 months.
- At least 8 coughs per hour, 24-hour cough frequency during the 14-day Run-In Period.
- Score ≥ 40 mm on cough severity VAS at Screening.
- Normal FEV1/FVC ratio of greater than 70% at Screening
Show all 9Show fewer
- A negative test for COVID-19.
- Women of child-bearing potential and men must agree to use a highly effective contraception method during the study and for at least 14 days after the last dose.
- Willing to carry study-related equipment as required for the study (e.g. cough monitor, phone).
Who cannot join
- Current smoker/vaper (all forms of smoking and inhaled substances, including cannabis/tobacco smoke and nicotine vapours) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history.
- Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, idiopathic pulmonary fibrosis, uncontrolled asthma or other serious pulmonary disease.
- Respiratory tract infection within 4 weeks before screening.
- History of malignancy in the last 5 years, unless it is a non-serious skin cancer.
- History of moderate or severe alcohol or drug use disorder within the last 3 years.
- Opioid use with in the 7 days prior to screening.
Show all 21Show fewer
- History of a positive serologic test for hepatitis B virus surface antigen, or hepatitis C virus.
- Previous participation in a clinical trial in the last 30 days or 6-half half-lives of test drug activity.
- Current participation in or completion of speech language therapy intervention therapy for chronic cough within 8 weeks prior to screening.
- Use of Prohibited medications within 4 weeks prior to screening and at any time during the study: anti-tussive therapy, systemic corticosteroids, ACE inhibitors, opioids.
- Gabapentin and pregabalin are prohibited unless they are being administered for treatment of a condition other than RCC and have been on a stable dose of that medication for at least 6 weeks prior to screening and plan to remain on that dose for the duration of the study.
- Tricyclic antidepressants are prohibited unless they are being administered for treatment of a condition other than RCC and have been on a stable dose of that medication for at least 12 weeks prior to screening and plan to remain on that dose for the duration of the study.
- Beta blockers are prohibited unless they are on a stable dose for at least 6 weeks prior to screening.
- Use of dietary supplements containing magnesium for the duration of the study.
- History of myocardial infarction or other cardiac disorders as follows:
- History of any of the following within 6 months prior to screening, myocardial infarction, stroke or transient ischemic attack, coronary revascularization (PCI or CABG), or heart failure.
- History of clinically significant arrhythmias, poorly controlled hypertension.
- Any condition that, in the opinion of the investigator, places the participant at high risk for an acute cardiovascular event including but not limited to: angina symptomatic peripheral arterial disease, severe valvular heart disease, planned cardiovascular intervention or surgery during the study period, baseline QTc interval >450 ms (men) or >470 ms (women), or any clinically significant ECG abnormality as determined by the Investigator.
- History of any clinically significant or psychiatric condition that, in the eyes of the Investigator or designee, would not be suitable for this study. Or if, in the eyes of the Investigator or designee may prove non-compliant to study procedures.
- Spouses or other family members with a chronic cough in the household.
- Living and working in an excessively loud workplace (e.g. building site).
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom3 sites, 3 recruiting
- Recruiting
The Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility U Floor, Belfast City Hospital
Belfast, BT9 7AB
Lorcan McGarvey, 857-233-2316, reach2@sctherapeutic.com
- Recruiting
Kings College Hospital
London, SE5 9RS
Surinder Birring, 857-233-2316, reach2@sctherapeutic.com
- Recruiting
Royal Brompton Hospital
London, SW3 6NP
Kian Fan Chung, 857-233-2316, reach2@sctherapeutic.com
About this study
Official title: A Randomized, Double-Blind, Placebo Controlled, Parallel-Arm Pilot Evaluation - to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough
This is a randomized placebo-controlled, parallel-arm study to determine the safety and efficacy of SC0032 in participants with RCC
Read the detailed description
There are three parts to this study and an optional fourth part:
- an optional Usability Sub-Study,
- Part 1: Two Week Treatment (Run-In) Period,
- Part 2:Three Week Treatment (Parallel Arm) Period and
- Part 3: Four Week No Treatment (Follow-Up) Period, Participants completing the three primary parts of the study will attend four study visits. Participation in the optional Usability sub-study does not require any additional visits, see Figure 1. Trial Schema. Participants who do not meet criteria for Part 2, the Parallel Arm Period, at the end of Part 1, the Run-In period, will only be required to attend two study visits and will not receive an active treatment. Participants who discontinue the study prior to completion will be asked to complete an Early Termination Visit.
- Being tested
- SC0032, Placebo
- Keywords
- RCC, UCC, Refractory Chronic Cough, Unexplained Chronic Cough, SC0032
- Medical subject headings
- Chronic Cough
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SC0032Combination product
Magnesium Chloride
PlaceboDevice
Sodium Chloride
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Sodium Chloride Receives: Device: Placebo |
| SC0032 | Experimental | Magnesium Chloride Receives: Combination Product: SC0032 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in mean % change from baseline in 24-hour cough frequency using the mean of Days -8 to -2 for last 7 days of baseline vs the mean of Days 13-19 last 7 days of the treatment period, using the HYFE continuous cough monitor).
Linear mixed model with log-transformed daily cough frequency as response variable, fixed effect for treatment, and random effects for participants; fitted model yields point estimate and 95% CI estimate of placebo-adjusted treatment effect
Measured: Day -8 to Day 19.
Secondary outcomes (19)
Time to onset of response based on median time (in days) from start of treatment to first day when mean treatment effect ≥30%, based on cumulative daily averages using the HYFE continuous cough monitor) from Day 1 to Day 20.
Kaplan-Meier survival analysis to estimate median time to response (with 95% confidence intervals); log-rank test to compare response times of the treatment groups Cox proportional hazards model with adjustment for mean baseline cough frequency will yield a hazard ratio and 95% CIs.
Measured: From Day 1 to Day 20
Determine duration of response (≥30% reduction relative to baseline) from baseline (mean of Days -8 to -2) vs the Follow up period (mean of Days 22-28, 29-35, 36-42 and 43-49).
Linear mixed model with log-transformed daily cough frequency as response variable, fixed effect for treatment, and random effects for participants; fitted model yields point estimate and 95% CI estimate of placebo-adjusted treatment effect over the follow up period.
The differences in the proportion of responders during each week of the follow up period will be evaluated using a Fisher's exact test.
Measured: Day -8 to Day 49
Change in number of cough bouts per 24-hour period, defined using inter-cough gap thresholds of 2.0s, from Day -14 to -2 and Day 1 to Day 21.
Linear mixed model with log-transformed daily bout frequency as response variable, fixed effect for treatment, and random effects for participants; fitted model yields point estimate and 95% CI estimate of placebo-adjusted treatment effect.
Measured: From Day -14 to Day 21
Change in Leicester Cough questionnaire (LCQ) score on Day 0 vs Day 21. A 19-item, patient-completed health-related quality of life (HRQoL) for chronic cough. Each item is rated on a 7-point Likert scale (1-7), with higher score indicates better QoL.
The change from baseline will be analysed using an Analysis of Covariance (ANCOVA) model. The model will include baseline measurement (Visit 2 - Day 0) as a covariate and Treatment as the main factor; and a Baseline*Treatment interaction term will be investigated. Type III sums of squares will be used.
The model will yield adjusted least-squares means for Placebo and SC0032, along with the placebo-SC0032 treatment difference with corresponding 95% confidence intervals. A p value will also be presented for the difference.
Measured: Day 0 to Day 21
Change in Cough Severity Visual Analogue Scale (CS-VAS) score (0-100mm line anchored with "no cough" at 0 mm and "worst cough imaginable" at 100 mm) from Day 0 and Day 21.
The change from baseline will be analysed using an Analysis of Covariance (ANCOVA) model. The model will include baseline measurement (Visit 2) as a covariate and Treatment as the main factor; and a Baseline*Treatment interaction term will be investigated. Type III sums of squares will be used.
The model will yield adjusted least-squares means for Placebo and SC0032, along with the placebo-SC0032 treatment difference with corresponding 95% confidence intervals. A p value will also be presented for the difference.
Measured: Day 0 to Day 21
Change in Patient Global Impression of Severity 5-point score (PGI-S) score from Day 0 and Day 21. Response options typically range from "None" to "Severe", with higher scores indicating greater symptom severity.
The distribution of PGI-S at Visit 3 (Day 21) between Placebo and SC0032 will be compared using a Cochran-Mantel-Haenszel test.
An ordered (proportional odds) logistic regression model will be used to quantify treatment effects and estimate odds ratios (at Visit 3, adjusted for PGIS score at Visit 2 (Day 0) ) with 95% confidence intervals.
Measured: Day 0 to Day 21
Change in categorical Patient Global Impression of Change (PGI-C) score from Day 0 and Day 21 analyzed as the proportion of participants achieving improvement on the 7-point scale. Response options range from "Very much improved" to "Very much worse."
The difference in proportion of participants achieving improvement will be analysed using a Fisher's exact test (or CMH if appropriate).
A binary logistic regression model (or ordinal equivalent) will be used to quantify treatment effects and estimate odds ratios with 95% confidence intervals.
Measured: Day 0 to Day 21
Change in Newcastle Laryngeal Hypersensitivity Questionnaire (LHQ) score from Day 0 and Day 21. A 14-item tool measuring subjective laryngeal sensory symptoms. Items are rated on a 7-point Likert scale, with lower scores indicating greater severity.
The change from baseline will be analysed using an Analysis of Covariance (ANCOVA) model. The model will include baseline measurement (Visit 2) as a covariate and Treatment as the main factor; and a Baseline*Treatment interaction term will be investigated. Type III sums of squares will be used.
The model will yield adjusted least-squares means for Placebo and SC0032, along with the placebo-SC0032 treatment difference with corresponding 95% confidence intervals. A p value will also be presented for the difference.
Measured: Day 0 to Day 21
Change in mean daily cough from Day -8 to -2 vs Day 13-19 in Daily Cough Numeric Rating Scale (CS-NRS), an 11-point PRO rating severity of their cough over the past 24 hours. The scale ranges from 0 ("no cough") to 10 ("worst possible cough").
Linear mixed model as per Item 1 (primary endpoint).
Measured: Day -8 to Day 19
Report incidence of treatment-emergent adverse events (TEAEs).
Descriptive summary of incidence of treatment-emergent adverse events by treatment according to SOC and Preferred Term; n (%) frequency for duration of study.
Measured: Day -14 to Day 49
Report the severity of TEAEs.
Descriptive summary of severity (number and % of mild, moderate, or severe) of treatment-emergent adverse events by treatment for duration of study according to SOC and Preferred Term; n (%) frequency.
Measured: Day -14 to Day 49
Change from in FEV₁ and FVC from Day -14 to Day 49 by treatment group.
Descriptive change distributions by treatment group.
Measured: Day -14 to Day 49
Report number and % of participants with ≥1 serious adverse event (SAE) for duration of study.
Descriptive summary by treatment according to SOC and Preferred Term; n (%) frequency.
Measured: Day -14 to Day 49
Difference in mean % change from baseline in 24-hour cough frequency. The mean of Days -8 to -2 (baseline) vs the mean of Days 1-7 and 8-12 (Parallel Arm period).
The same model used in the primary objective (Item 1) will be applied.
Measured: Day -8 to Day 12
Determine the duration of response of SC0032 vs placebo by identifying the last week post-treatment when the mean treatment effect remains ≥20% reduction and ≥50% reduction.
Difference in mean % change in cough frequency between Day 22-28, 29-35, 36-42, 43-49 (Follow-up Period) and mean % change in cough frequency for Day -8 to -2 (baseline), SC0032 vs placebo. Descriptive and inferential comparison (as per item 3; for ≥20% reduction and ≥50% reduction thresholds.
Measured: Day -8 to Day 49
Define time to onset of effect based on cough bouts analyzed as per Objective 2 ((≥30% reduction), time course of treatment as per Objective 3 (baseline (mean of Days -8 to -2) vs the Follow up period (mean of Days 22-28, 29-35, 36-42 and 43-49).
Time to onset will be analysed as per Objective 2, time course of treatment as per Objective 3 and the cough to bout ratio will be analysed using a linear mixed model (as per the primary).
Measured: Day -8 to Day 49
Change in number, duration, and coughs per bout across definitions using linear mixed model with treatment group as a fixed effect, study day as a repeated-measure and random effects for participants between Day -14 to -2 and Day 1 to Day 21.
Compare number, duration, and coughs per bout across definitions using linear mixed model with treatment group as a fixed effect, study day as a repeated-measure and random effects for participants.
Measured: Day -14 to Day 21
Change in PRO's (CS-VAS, PGI-S, LCQ, LHQ) from Day -14 to Day 0 and Day 21 to Day 49.
Descriptive summaries and change from Visit 1 (Day -14) to Visit 2 (Day 0) and from Visit 3 (Day 21) to Visit 4 (Day 49). All ANCOVAs as per Item 5. Except PGI-S which will be analyzed as per Item 7, along with descriptive summaries.
Measured: Day -14 to Day 49
The proportion of participants with a clinically meaningful change in PGI-C at Visit 4 -Day 49.
Descriptive summaries of actual values at Visit 4 (Day 49) by treatment group, as per Item 8.
Measured: Day -14 to Day 49
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2026
- Study start13 Jul 2026
- Primary completionJan 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Refractory Chronic Cough and Unexplained Chronic CoughStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Combination product SC0032 versus placebo.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sensory Cloud, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07690059
- Sponsor's protocol ID
- SC-RCC-UK002
- Acronym
- SensoryCloud
- Status last verified
- Oct 2026
- First submitted
- 5 Jun 2026
- Last updated
- 14 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo Controlled, Parallel-Arm Pilot Evaluation - to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough
- ClinicalTrials.gov ID
- NCT07690059
- Acronym / sponsor ID
- SensoryCloud / SC-RCC-UK002
- Keywords
- RCC, UCC, Refractory Chronic Cough, Unexplained Chronic Cough, SC0032
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Sensory Cloud, Inc.Industry (pharma, biotech, devices)
- Study start
- 13 Jul 2026 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 8 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized placebo-controlled, parallel-arm study to determine the safety and efficacy of SC0032 in participants with RCC
Detailed description
There are three parts to this study and an optional fourth part:
- an optional Usability Sub-Study,
- Part 1: Two Week Treatment (Run-In) Period,
- Part 2:Three Week Treatment (Parallel Arm) Period and
- Part 3: Four Week No Treatment (Follow-Up) Period, Participants completing the three primary parts of the study will attend four study visits. Participation in the optional Usability sub-study does not require any additional visits, see Figure 1. Trial Schema. Participants who do not meet criteria for Part 2, the Parallel Arm Period, at the end of Part 1, the Run-In period, will only be required to attend two study visits and will not receive an active treatment. Participants who discontinue the study prior to completion will be asked to complete an Early Termination Visit.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Combination product SC0032 versus placebo.
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Device: PlaceboSodium Chloride |
| SC0032 | Experimental | Combination Product: SC0032Magnesium Chloride |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Males and females between 18 and 80 years.
- Capable of giving signed informed consent.
- Diagnosed with RCC (including unexplained chronic cough) for at least 6 months.
- At least 8 coughs per hour, 24-hour cough frequency during the 14-day Run-In Period.
- Score ≥ 40 mm on cough severity VAS at Screening.
Key exclusion criteria (21 listed)
- Current smoker/vaper (all forms of smoking and inhaled substances, including cannabis/tobacco smoke and nicotine vapours) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history.
- Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, idiopathic pulmonary fibrosis, uncontrolled asthma or other serious pulmonary disease.
- Respiratory tract infection within 4 weeks before screening.
- History of malignancy in the last 5 years, unless it is a non-serious skin cancer.
- History of moderate or severe alcohol or drug use disorder within the last 3 years.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SC0032Magnesium Chloride | Combination product | SC0032 |
| PlaceboSodium Chloride | Device | Placebo |
Primary outcome
Difference in mean % change from baseline in 24-hour cough frequency using the mean of Days -8 to -2 for last 7 days of baseline vs the mean of Days 13-19 last 7 days of the treatment period, using the HYFE continuous cough monitor).
Time frame: Day -8 to Day 19.
Linear mixed model with log-transformed daily cough frequency as response variable, fixed effect for treatment, and random effects for participants; fitted model yields point estimate and 95% CI estimate of placebo-adjusted treatment effect
19 secondary outcomes
Time to onset of response based on median time (in days) from start of treatment to first day when mean treatment effect ≥30%, based on cumulative daily averages using the HYFE continuous cough monitor) from Day 1 to Day 20.
Time frame: From Day 1 to Day 20
Determine duration of response (≥30% reduction relative to baseline) from baseline (mean of Days -8 to -2) vs the Follow up period (mean of Days 22-28, 29-35, 36-42 and 43-49).
Time frame: Day -8 to Day 49
Change in number of cough bouts per 24-hour period, defined using inter-cough gap thresholds of 2.0s, from Day -14 to -2 and Day 1 to Day 21.
Time frame: From Day -14 to Day 21
Change in Leicester Cough questionnaire (LCQ) score on Day 0 vs Day 21. A 19-item, patient-completed health-related quality of life (HRQoL) for chronic cough. Each item is rated on a 7-point Likert scale (1-7), with higher score indicates better QoL.
Time frame: Day 0 to Day 21
Change in Cough Severity Visual Analogue Scale (CS-VAS) score (0-100mm line anchored with "no cough" at 0 mm and "worst cough imaginable" at 100 mm) from Day 0 and Day 21.
Time frame: Day 0 to Day 21
Change in Patient Global Impression of Severity 5-point score (PGI-S) score from Day 0 and Day 21. Response options typically range from "None" to "Severe", with higher scores indicating greater symptom severity.
Time frame: Day 0 to Day 21
Change in categorical Patient Global Impression of Change (PGI-C) score from Day 0 and Day 21 analyzed as the proportion of participants achieving improvement on the 7-point scale. Response options range from "Very much improved" to "Very much worse."
Time frame: Day 0 to Day 21
Change in Newcastle Laryngeal Hypersensitivity Questionnaire (LHQ) score from Day 0 and Day 21. A 14-item tool measuring subjective laryngeal sensory symptoms. Items are rated on a 7-point Likert scale, with lower scores indicating greater severity.
Time frame: Day 0 to Day 21
Change in mean daily cough from Day -8 to -2 vs Day 13-19 in Daily Cough Numeric Rating Scale (CS-NRS), an 11-point PRO rating severity of their cough over the past 24 hours. The scale ranges from 0 ("no cough") to 10 ("worst possible cough").
Time frame: Day -8 to Day 19
Report incidence of treatment-emergent adverse events (TEAEs).
Time frame: Day -14 to Day 49
Report the severity of TEAEs.
Time frame: Day -14 to Day 49
Change from in FEV₁ and FVC from Day -14 to Day 49 by treatment group.
Time frame: Day -14 to Day 49
Report number and % of participants with ≥1 serious adverse event (SAE) for duration of study.
Time frame: Day -14 to Day 49
Difference in mean % change from baseline in 24-hour cough frequency. The mean of Days -8 to -2 (baseline) vs the mean of Days 1-7 and 8-12 (Parallel Arm period).
Time frame: Day -8 to Day 12
Determine the duration of response of SC0032 vs placebo by identifying the last week post-treatment when the mean treatment effect remains ≥20% reduction and ≥50% reduction.
Time frame: Day -8 to Day 49
Define time to onset of effect based on cough bouts analyzed as per Objective 2 ((≥30% reduction), time course of treatment as per Objective 3 (baseline (mean of Days -8 to -2) vs the Follow up period (mean of Days 22-28, 29-35, 36-42 and 43-49).
Time frame: Day -8 to Day 49
Change in number, duration, and coughs per bout across definitions using linear mixed model with treatment group as a fixed effect, study day as a repeated-measure and random effects for participants between Day -14 to -2 and Day 1 to Day 21.
Time frame: Day -14 to Day 21
Change in PRO's (CS-VAS, PGI-S, LCQ, LHQ) from Day -14 to Day 0 and Day 21 to Day 49.
Time frame: Day -14 to Day 49
The proportion of participants with a clinically meaningful change in PGI-C at Visit 4 -Day 49.
Time frame: Day -14 to Day 49
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Refractory Chronic Cough and Unexplained Chronic Cough
Not yet recruitingPhase 4
A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
Cough, Refractory Chronic Cough
RecruitingPhase 2
Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough
Chronic Cough (CC), Refractory Chronic Cough
Active, not recruitingPhase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Cough, Refractory Chronic Cough
RecruitingPhase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
Refractory Chronic Cough
Active, not recruitingPhase 2
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
Refractory or Unexplained Chronic Cough
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The Wellcome Trust-Wolfson Northern Ireland Clinical Research Facility U Floor, Belfast City Hospital
Belfast, United Kingdom
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing SC0032 in people with Refractory Chronic Cough and Unexplained Chronic Cough, run by Sensory Cloud, Inc. at 3 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in mean % change from baseline in 24-hour cough frequency using the mean of Days -8 to -2 for last 7 days of baseline vs the mean of Days 13-19 last 7 days of the treatment period, using the HYFE continuous cough monitor). (time frame: Day -8 to Day 19.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2026.